

Systemic Juvenile Idiopathic Arthritis

What is systemic juvenile idiopathic arthritis?

Systemic juvenile idiopathic arthritis (sJIA) is a subtype of juvenile idiopathic arthritis (JIA), a group of conditions characterised by chronic arthritis in children. Other subtypes include oligoarticular JIA and polyarticular JIA.

JIA affects approximately 100 in every 100,000 children¹ of which sJIA accounts for 10 to 20 percent.² In Europe and North America the incidence of disease is the same in both sexes, unlike the female predominance seen in other subtypes of JIA.¹ sJIA differs from the other types of JIA by having severe systemic symptoms such as a spiking fever, in addition to the arthritis. Despite conventional therapies, a significant number of children are often left with serious and life-long complications such as growth defects and osteoporosis.¹

Characteristics of sJIA

sJIA begins in children aged 16 years or younger with a peak age of onset between 18 months and two years, although persistence of the disease into adulthood does occur.¹ The arthritis is accompanied by a characteristic fever, skin rash, anaemia, enlargement of the liver and/or spleen and inflammation of the lining of the heart and/or lungs.¹

The impact of sJIA

sJIA presents a huge daily burden for the children and families affected. One-half to two-thirds of patients develop chronic and persistent arthritis and approximately half of these children are left with significant disability.²

The disease can disturb emotional development and psychological support for the child and their family is often required.¹ Extra support may be needed at school to ensure educational progress and help the child to integrate with their peers. Previous studies have indicated that these children are more socially isolated and have higher rates of unemployment later in life.¹

Long-term prognosis

The severity and outcomes of sJIA are unpredictable. Some children may be free of disease within two to four years, whereas others experience a relapsing course with both systemic and arthritic symptoms.¹ Patients with severe disease often have to endure active arthritis well into adult life despite treatment with existing therapies.¹ In two large European studies, 23 to 30 percent of children had systemic symptoms 10 to 15 years after the initial onset of sJIA.¹

Serious, life-threatening complications occur much more frequently in sJIA than in other types of rheumatic disease and the overall mortality rate is estimated to be between two to four percent.³ One severe, life-threatening complication is macrophage activation syndrome (MAS), a systemic inflammatory reaction caused by the excessive activation and multiplication of particular immune system cells.²

The treatment challenge

sJIA has the worst long-term prognosis compared to other types of JIA, yet current medical treatment is considered unsatisfactory.¹ Mild forms of disease are usually treated with non-steroidal anti-inflammatory drugs. High dose corticosteroids are often necessary to control systemic symptoms, but do not improve the long-term prognosis and their use is accompanied by severe side effects.¹

Treatment with traditional arthritis medications such as methotrexate (MTX) is of little benefit and only 30 percent of children respond to anti-tumour necrosis factor (anti-TNF) therapy.¹

IL-6: The hidden key?

A large body of evidence demonstrates the critical role of interleukin-6 (IL-6) in sJIA and explains why this messenger substance is a promising target for future therapies.

Studies have shown that patients with sJIA have significantly higher levels of IL-6 in their blood and joints compared to other types of JIA or adult rheumatoid arthritis (RA).² IL-6 contributes to all the major features of sJIA including joint inflammation, joint damage, fever, anaemia, growth impairment and osteoporosis.²

Genetic research suggests that a mutation in the IL-6 gene could be responsible for its increased production in sJIA.² Secretion of IL-1, another pro-inflammatory

messenger, is also high in sJIA and clinical trials of biologic drugs that block either IL-1 or IL-6 have seen good results.¹

RoACTEMRA/ACTEMRA: A new treatment for sJIA

A new biologic drug, developed by Roche in collaboration with Chugai, provides a promising new treatment option for children with sJIA. RoACTEMRA (tocilizumab, ACTEMRA outside the EU) is the first fully humanised monoclonal antibody that targets the IL-6 receptor. Data from the global Phase III TENDER study showed 85 percent of patients achieved 30 percent improvement (JIA ACR30) in the signs and symptoms of sJIA and absence of fever, a primary characteristic of sJIA, following three months treatment with RoACTEMRA. Further data showed 70 percent achieved JIA ACR70 and 37 percent achieved ACR90. In addition to the significant improvement in ACR responses, nearly two thirds were free of rash after three months.⁴

RoACTEMRA is already approved in the EU and US for adult RA, a disease also associated with elevated levels of IL-6 and systemic symptoms such as fatigue, anaemia and fever. Studies in RA have demonstrated RoACTEMRA's strong efficacy and safety, with consistently high remission rates across all patient types⁵ and inhibition of structural joint damage.⁶ In addition, it is the only product to have proven superiority to methotrexate in monotherapy in ACR20, ACR50 and ACR70 responses at six months, in adult RA.⁷

References

¹ Woo, P. Systemic juvenile rheumatoid arthritis: diagnosis, management, and outcome. *Nature Clinical Practice: Rheumatology*. 2006. 2:1

² De Benedetti F. Inflammatory cytokines in the pathogenesis and treatment of systemic juvenile idiopathic arthritis – Basic science for the clinician. *Pediatric Rheumatology Online Journal* 2005. Vol 3:2

³ Cassidy JT, *et al.* Juvenile rheumatoid arthritis. Cassidy JT, Petty RE, eds. *Textbook of Pediatric Rheumatology*. 2001:218–322

⁴ De Benedetti F *et al.* Efficacy and safety of tocilizumab in patients with systemic Juvenile Idiopathic Arthritis (sJIA): 12-week data from the phase III TENDER trial. Poster presented at EULAR 2010

⁵ Long-term efficacy of tocilizumab in rheumatoid arthritis for up to 3.5 years. Smolen J *et al.* Oral presentation at ACR, 18th October 2009

⁶ LITHE: Tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients (Pts) at 2 years with increasing clinical efficacy over time. Fleischmann, R *et al.* Oral presentation at ACR, 18th October 2009

⁷ Jones G, *et al.* Efficacy of Tocilizumab (TCZ) VS Methotrexate (MTX) Monotherapy in Patients with Rheumatoid Arthritis (RA) with No Prior MTX or DMARD Exposure. Abstract presented on 12th June 2009 at EULAR.

